Catalent adds fast-dissolve tech to oral dose arsenal

Adding to its store of technology weapons, Catalent Pharma can now offer fast-dissolve tablet technology to clients. It obtained the development rights to Lyopan from Pantec.

The lyophilized tablets are used for such OTC products as allergy treatments and travel medications, says Catalent. The technology uses less water than other oral dose technologies, reducing not just energy consumption but also sublimation and drying time.  

Lyopan adds to the oral dose technology subset of Catalent's drug delivery technology offerings. Among them are Zydis fast dissolve, a freeze-dried oral solid dosage form that disperses in the mouth, without water.

The manufacturing and packaging contractor announced last fall a deal with digital-ID solutions provider Digimarc for so-called media-enhanced packaging. The technology incorporates coding that allows consumers can connect via smart phone to product content that supplements label information.

- here's the Catalent release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.